Severe Outcomes Associated With SARS-CoV-2 Infection in Children: A Systematic Review and Meta-Analysis

Madeleine W Sumner1, Alicia Kanngiesser2, Kosar Lotfali-Khani3

  • 1Schulich School of Medicine and Dentistry, Western University, London, ON, Canada.

Insights

The proportion of children hospitalized with SARS-CoV-2 infection was 3.3%, with higher rates early in the pandemic. Severe outcomes, intensive care unit (ICU) admission, and death were infrequent but varied by study factors.

Area of Science:

  • Pediatric infectious diseases
  • Epidemiology
  • Public health

Background:

  • Estimating the burden of SARS-CoV-2 infection in children is crucial for public health planning.
  • Previous estimates of severe outcomes in pediatric COVID-19 cases vary widely.

Approach:

  • A systematic review and meta-analysis of 118 studies involving over 3.3 million children infected with SARS-CoV-2.
  • Searched PubMed, Embase, and MedRxiv for studies published between December 2019 and May 2021.
  • Pooled data using random effects models following PRISMA guidelines.

Key Points:

  • Community-based studies reported 3.3% hospitalization, 0.3% ICU admission, 0.1% severe outcomes, and 0.02% mortality.
  • Hospital-based screening studies reported higher rates: 23.9% hospitalization, 2.9% ICU admission, 1.3% severe outcomes, and 0.2% mortality.
  • Estimates were influenced by study population, risk of bias, country income, and pandemic timing, with later studies showing increased ICU admissions and severe outcomes.

Conclusions:

  • While severe outcomes, ICU admission, and death are uncommon in children with SARS-CoV-2, hospitalization rates were approximately 3.3%.
  • Variations in reported outcomes highlight the importance of considering study design, population, and the evolving nature of the pandemic.
  • These findings are relevant for understanding pediatric COVID-19 burden and informing clinical and public health strategies.
Abstract

Related Concept Videos

Pneumonia III: Complications and Assessment01:30

Pneumonia III: Complications and Assessment

Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
425
Pneumonia II: Pathophysiology01:29

Pneumonia II: Pathophysiology

The pathophysiology of pneumonia involves the following steps:
511
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
41
Acute Respiratory Failure-II01:21

Acute Respiratory Failure-II

Type I Respiratory Failure, or hypoxemic respiratory failure, occurs when the partial pressure of oxygen (PaO2) in arterial blood falls below 60 mmHg while breathing room air without a corresponding increase in arterial carbon dioxide levels (PaCO2). This condition highlights a significant impairment in the lungs' capacity to oxygenate the blood.
The underlying physiological abnormalities that contribute to hypoxemic respiratory failure include:
343
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
501
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
5.4K